Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · September 25, 2023

Cost-Effectiveness of Vericiguat in Patients With HFrEF



Additional Info

Disclosure statements are available on the authors' profiles:

Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial
Circulation 2023 Sep 06;[EPub Ahead of Print], DS Chew, Y Li, R Bigelow, PA Cowper, KJ Anstrom, MR Daniels, L Davidson-Ray, AF Hernandez, CM O'Connor, PW Armstrong, DB Mark

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading